Menopause's Impact on Multiple Sclerosis and Neurological Conditions in Women
A systematic review found that menopause influences symptoms and disease expression in multiple sclerosis (MS). Specifically, perimenopause and postmenopause can exacerbate symptom overlap between age-related issues and MS, potentially speeding up disability progression despite lower relapse rates.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Moderate
- Outcome
- Not reported
Why it matters
Understanding the menopausal effects on MS and similar neurological conditions is crucial for managing symptoms and improving patient care for women in this demographic.
What this does not prove
The review focuses solely on hormonal changes during menopause and their effects on neurological conditions without establishing new clinical trials or outcomes.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-23
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Women in menopause
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Oral estrogen-containing systemic menopause hormone therapy is associated with increased thromboembolic events including stroke, while transdermal regimens appear safer.
Original sources
- Primary evidenceMenopause and Neurology: Clinical Essentials. ↗DOI: 10.1212/cpj.0000000000200678
Supporting passages (8)
study designPublication types: Journal Article; Review
subjectsMeSH terms: Humans; Menopause; Female; Nervous System Diseases; Epilepsy; Neurology; Estrogen Replacement Therapy; Estrogens
populationIn MS, perimenopause and postmenopause contribute to overlapping age-related and MS-related symptoms and is a period of high clinical need with potential acceleration in disability progression despite reduced relapse rate.
findingsThis review summarizes the physiology and hormonal changes of spontaneous menopause and its treatment as applied to cognition, epilepsy, migraine, multiple sclerosis (MS), and stroke.
safety signalsOral estrogen-containing systemic menopause hormone therapy (MHT) is associated with increased thromboembolic events (including stroke), whereas transdermal regimens seem safer and are preferred at low or standard doses (≤50 mcg estradiol patch or ≤1.5 mg [or 2 pumps] per day of 0.06% estradiol gel).
publication datePublication date: 2026-10-23
limitationsTitle: Menopause and Neurology: Clinical Essentials.
peer reviewedPublication types: Journal Article; Review
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.